NR4A1 and breast cancer: In a recent retrospective study of 257 male BC patients, we showed that adjuvant treatment with TAM was associated with a 1.4-fold decreased risk of cancer mortality compared to AI treatment.2 Via matching analysis among male and female patients with hormone receptor-positive breast cancer, we demonstrated clearly that the benefit of TAM treatment in male BC is comparable with the effect of TAM in female BC.3